Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 7/2017

01-07-2017 | Review

Novel and Experimental Therapies in Chronic Pancreatitis

Authors: Soumya Jagannath, Pramod Kumar Garg

Published in: Digestive Diseases and Sciences | Issue 7/2017

Login to get access

Abstract

Chronic pancreatitis (CP) is a progressive inflammatory disease of the pancreas. The currently available treatment of CP is aimed at controlling symptoms and managing complications. Unfortunately, no specific treatment is available to halt the progression of the disease process because the pathophysiological perturbations in CP are not well understood. In this review, we discuss various therapeutic targets and investigational agents acting on these targets. Among these, therapies modulating immune cells and those acting on pancreatic stellate cells appear promising and may translate into clinical benefit in near future. However, these experimental therapies are mostly in animal models and they do not recapitulate all aspects of human disease. Still they may be beneficial in developing effective therapeutic modalities to curb inflammation in chronic pancreatitis.
Literature
1.
Whitcomb DC, Frulloni L, Garg P, Greer JB, et al. Chronic pancreatitis: an international draft consensus proposal for a new mechanistic definition. Pancreatology. 2016;16:218–224.CrossRefPubMed
2.
The Copenhagen Pancreatic Study Group. An interim report from a prospective epidemiological multicentre study. Scand J Gastroenterol. 1981;16:305–312.CrossRef
3.
Robles-Diaz G, Vargas F, Uscanga L, Fernandez-del Castillo C. Chronic pancreatitis in Mexico City. Pancreas. 1990;5:479–483.CrossRefPubMed
4.
Garg PK, Tandon RK. Survey on chronic pancreatitis in the Asia-Pacific region. J Gastroenterol Hepatol. 2004;19:998–1004.CrossRefPubMed
5.
Lin Y, Tamakoshi A, Matsuno S, Takeda K, et al. Nationwide epidemiological survey of chronic pancreatitis in Japan. J Gastroenterol. 2000;35:136–141.CrossRefPubMed
6.
Balaji LN, Tandon RK, Tandon BN, Banks A. Prevalence and clinical features of chronic pancreatitis in southern India. Int J Pancreatol. 1994;15:29–34.PubMed
7.
Etemad B, Whitcomb DC. Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology. 2001;120:682–707.CrossRefPubMed
8.
Tandon RK, Sato N, Garg PK. Chronic pancreatitis: Asia-Pacific consensus report. J Gastroenterol Hepatol. 2002;17:508–518.CrossRefPubMed
9.
Rösch T, Daniel S, Scholz M, Huibregtse K, European Society of Gastrointestinal Endoscopy Research Group. Endoscopic treatment of chronic pancreatitis: a multicenter study of 1000 patients with long-term follow-up. Endoscopy. 2002;34:765–771.CrossRefPubMed
10.
Cahen DL, Gouma DJ, Nio Y, Rauws EJ, et al. Endoscopic versus surgical drainage of the pancreatic duct in chronic pancreatitis. N Engl J Med. 2007;356:676–684.CrossRefPubMed
11.
Xue J, Sharma V, Habtezion A. Immune cells and immune-based therapy in pancreatitis. Immunol Res. 2014;58:378–386.CrossRefPubMed
12.
Zimnoch L, Szynaka B, Puchalski Z. Mast cells and pancreatic stellate cells in chronic pancreatitis with differently intensified fibrosis. Hepatogastroenterology. 2002;49:1135–1138.PubMed
13.
Schmitz-Winnenthal H, Pietsch DH, Schimmack S, Bonertz A, et al. Chronic pancreatitis is associated with disease-specific regulatory T-cell responses. Gastroenterology. 2010;138:1178–1188.CrossRefPubMed
14.
Grundsten M, Liu GZ, Permert J, Hjeilmstrom P, Tsai JA. Increased central memory T cells in patients with chronic pancreatitis. Pancreatology. 2005;5:177–182.CrossRefPubMed
15.
Marrache F, Pendyala S, Bhagal G, Betz KS, Song Z, Wang TC. Role of bone marrow derived cells in experimental chronic pancreatitis. Gut. 2008;57:1113–1120.CrossRefPubMed
16.
Lardon J, Rooman I, Bouwens L. Nestin expression in pancreatic stellate cells and angiogenic endothelial cells. Histochem Cell Biol. 2002;117:535–540.CrossRefPubMed
17.
18.
Xue J, Sharma V, Hsieh MH, Chawla M, et al. Alternatively activated macrophages promote pancreatic fibrosis in chronic pancreatitis. Nature communications. 2015;6:7158.CrossRefPubMedPubMedCentral
19.
Baumert J-T, Sparmann G, Emmrich J, Stefan L, Jaster R. Inhibitory effect of interferons on pancreatic stellate cell activation. World J Gastroenterol. 2006;12:896–901.CrossRefPubMedPubMedCentral
20.
Zhao HF, Ito T, Gibo J, Kawabe K, et al. Anti-monocyte chemoattractant protein 1 gene therapy attenuates experimental chronic pancreatitis induced by dibutyltin dichloride in rats. Gut. 2005;54:1759–1767.CrossRefPubMedPubMedCentral
21.
Su SB, Xie MJ, Sawabu N, Motoo Y. Supressive effect of herbal medicine Saiko-Keishi-to on acinar cell apoptosis in rat spontaneous chronic pancreatitis. Pancreotology. 2007;7:28–36.CrossRef
22.
Su SB, Motoo Y, Xie MJ, Taga H, Sawabu N. Antifibrotic effect of herbal medicine Saiko-Keishi-to (TJ-10) on chronic pancreatitis in the WBN/KOB rat. Pancreas. 2001;22:8–17.CrossRefPubMed
23.
Masamune A, Suzuki N, Kikuta K, Satoh M, Satoh K, Shimosewaga T. Curcumin blocks activation of pancreatic stellate cells. J Cell Biochem. 2006;95:1080–1093.CrossRef
24.
Wei L, Yamamoto M, Harada M, Otsuki M. Treatment with pravastatin attenuates progression of chronic pancreatitis in rat. Lab Invest. 2011;91:872–884.CrossRefPubMed
25.
Jaster R, Brock P, Sparmann G, Emmrich J, Liebe S. Inhibition of pancreatic stellate cell activation by the hydroxymethylglutaryl coenzyme A reductase inhibitor Lovastatin. Biochem Pharmacol. 2003;65:1295–1303.CrossRefPubMed
26.
27.
Kuno A, Yamada T, Masuda K, Ogawa K, et al. Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats. Gastroenterology. 2003;124:1010–1019.CrossRefPubMed
28.
Skipworth JR, Nijmeijer RM, van Santvoort HC, Besselink MG, et al. The effect of renin angiotensin system genetic variants in acute pancreatitis. Ann Surg. 2015;261:180–188.CrossRefPubMed
29.
Madro A, Kurzepa J, Celinski K, Slomka M, et al. Effects of renin-angiotensin system inhibitors on fibrosis in patients with alcoholic chronic pancreatitis. J Physiol Pharmacol. 2016;67:103–110.PubMed
30.
Tamura Y, Hirado M, Okamura K, Minato Y, Fujii S. Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r, and C1 esterase. Biochim Biophys Acta Enzymol. 1977;484:417–422.CrossRef
31.
Gibo J, Ito T, Kawabe K, Hisano T, et al. Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity. Lab Inv. 2005;85:75–89. CrossRef
32.
Otsuki M, Okhi A, Okabayashi Y, Suehiro I, Baba S. Effect of synthetic protease inhibitor camostat on pancreatic exocrine function in rats. Pancreas. 1987;2:164–169.CrossRefPubMed
33.
Kisfalvi K, Papp M, Friess H, Buchler M, Goracz UG. Beneficial effects of oral administration of camostat on cerulein-induced pancreatitis in rats. Dig Dis Sci. 1995;40:546–547.CrossRefPubMed
34.
Ito T, Otsuki M, Itoi T, Shimosegawa T, et al. Pancreatic diabetes in a follow-up survey of chronic pancreatitis in Japan. J Gastroenterol. 2007;42:291–297.CrossRefPubMed
35.
Jaster R, Hilgendorf I, Fitzner B, Brock P, et al. Regulation of pancreatic stellate cell function in vitro: biological and molecular effects of all-trans retinoic acid. Biochem Pharmacol. 2003;66:633–641.CrossRefPubMed
36.
Li XC, Lu XL, Chen HH. α-Tocopherol treatment ameliorates chronic pancreatitis in an experimental rat model induced by trinitrobenzene sulfonic acid. Pancreatology. 2011;11:5–11.CrossRefPubMed
37.
Yoo BM, Oh TY, Kim YB, Yeo Y, et al. Novel antioxidant ameliorates the fibrosis and inflammation of cerulein-induced chronic pancreatitis in a mouse model. Pancreatology. 2005;5:165–176.CrossRefPubMed
38.
39.
Suzuki N, Masamune A, Kikuta K, Watanabe T, Satoh K, Shimosegawa K. Ellagic acid inhibits pancreatic fibrosis in male Wistar Bonn/Kobori rats. Dig Dis Sci. 2009;54:802–810.CrossRefPubMed
40.
Masamune A, Kikuta K, Satoh M, Suzuki N, Shimosewaga T. Green tea polyphenol epigallocatechin-3-gallate blocks PDGF-induced proliferation and migration of rat pancreatic stellate cells. World J Gastroenterol. 2005;11:3368–3374.CrossRefPubMedPubMedCentral
41.
Asaumi H, Wantabe S, Taguchi M, et al. Green tea polyphenol (-) -epigallocatechin-3-gallate inhibits ethanol induced activation of pancreatic stellate cells. Eur J Clin Invest. 2006;36:113–122.CrossRefPubMed
42.
Jaster R, Sparmann G, Emmrich J, Liebe S. Extracellular signal regulated kinases are key mediators of mitogenic signals in rat pancreatic stellate cells. Gut. 2002;51:579–584.CrossRefPubMedPubMedCentral
43.
Lin Z, Zheng LC, Zhang HZ, Tsang SW, Bian ZX. Antifibrotic effects of phenolic compounds on pancreatic stellate cells. BMC Complement Altern Med. 2015;15:259.CrossRefPubMedPubMedCentral
44.
Zion O, Genin O, Kawada N, Yoshizato K, et al. Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention. Pancreas. 2009;38:427–435.CrossRefPubMed
45.
Niina Y, Ito T, Oono T, Nakamura T, Fujimori N, et al. A sustained prostacyclin analog, ONO-1301, attenuates pancreatic fibrosis in experimental chronic pancreatitis induced by dibutyltin dichloride in rats. Pancreatology. 2014;14:201–210.CrossRefPubMed
46.
Reding T, Bimler D, Perren A, Sun LK, et al. A selective COX-2 inhibitor suppresses chronic pancreatitis in an animal model (WBN/Kob rats): significant reduction of macrophage infiltration and fibrosis. Gut. 2006;55:1165–1173.CrossRefPubMedPubMedCentral
47.
Wei L, Yamamoto M, Harada M, Otsuki M. Treatment with pravastatin attenuates progression of chronic pancreatitis in rat. Lab Inv. 2011;91:872–884.CrossRef
48.
Zhou CH, Lin-Li, Zhu XY, Wen-Tang, et al. Protective effects of edaravone on experimental chronic pancreatitis induced by dibutyltin dichloride in rats. Pancreatology. 2013;13:125–132.CrossRefPubMed
49.
Yang T, Liang Y, Lin Q, Liu J, et al. miR-29 mediates TGF β1-induced extracellular matrix synthesis through activation of PI3K-AKT pathway in human lung fibroblasts. J Cell Biochem. 2013;114:1336–1342.CrossRefPubMed
50.
Xiong M, Jiang L, Zhou Y, Qiu W, et al. The miR- 200 family regulates TGF-b1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. Am J Physiol Renal Physiol. 2012;302:F369–F379.CrossRefPubMed
51.
Zhu H, Luo H, Li Y, Zhou Y, et al. MicroRNA-21 in scleroderma fibrosis and its function in TGF-beta-regulated fibrosis-related genes expression. J Clin Immunol. 2013;33:1100–1109.CrossRefPubMed
52.
Zarjou A, Yang S, Abraham E, Agarwal A, Liu G. Identification of a micro RNA signature in renal fibrosis: role of miR-21. Am J Physiol Renal Physiol. 2011;301:F793–F801.CrossRefPubMedPubMedCentral
53.
54.
Midha S, Hasan A, Dhingra R, Garg PK. Long-term pain relief with optimized medical including antioxidants and step-up interventional therapy in patients with chronic pancreatitis. J Gastroenterol Hepatol. 2016;32:270–277. doi:10.​1111/​jgh.​13410.
55.
Garg PK. Antioxidants for chronic pancreatitis: reasons for disappointing results despite sound principles. Gastroenterology. 2013;144:e19–e20.CrossRefPubMed
56.
Tang Y, Laio Y, Kawaguchi-Sakita N, Raut V, et al. Sinisan, a traditional Chinese medicine, attenuates experimental chronic pancreatitis induced by trinitrobenzene sulfonic acid in rats. J Hepatobiliary Pancreat Sci. 2011;18:551–558.CrossRefPubMed
57.
Shiratori K, Takeuchi T, Satake K, Matsuno S. Clinical evaluation of oral administration of a cholecystokinin A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose response study in Japan. Pancreas. 2002;25:e15.CrossRef
58.
Levenick JM, Andrews CL, Purich ED, Gordon SR, Gardner TB. A phase II trial of human secretin infusion for refractory type B pain in chronic pancreatitis. Pancreas. 2013;42:596–600.CrossRefPubMed
59.
Zhang L, Kline RH, McNearney TA, Johnson MP, Westlund KN. Cannabinoid receptor 2 agonist attenuates pain related behavior in rats with chronic alcohol/high fat diet induced pancreatitis. Mol Pain. 2014;10:66.CrossRefPubMedPubMedCentral
60.
Wang Y, Li Y, Wang L, Kang Y, et al. Tanshinone IIA attenuates chronic pancreatitis- induced pain in rats via downregulation of HMGB1 and TRL4 expression in the spinal cord. Pain Phys. 2015;18:E615–E628.
61.
Ceppa E, Cattaruzza F, Lyo V, Amadesi S, et al. Transient receptor potential ion channels V4 and A1 contribute to pancreatitis pain in mice. Am J Physiol Gastrointest Liver Physiol. 2010;299:G556–G571.CrossRefPubMedPubMedCentral
62.
Zhang LP, Ma F, Abshire SM, Westlund KN. Prolonged high fat/alcohol exposure increases TRPV4 and its functional responses in pancreatic stellate cells. Am J Physiol Regul Integr Comp Physiol. 2013;304:R702–R711.CrossRefPubMedPubMedCentral
63.
Zhang LP, Kline RH, Deevska IG, Ma F, et al. Alcohol and high fat induced chronic pancreatitis: TRPV4 antagonist reduces hypersensitivity. Neuroscience. 2015;311:166–179.CrossRefPubMedPubMedCentral
64.
Kapural L, Cywinski JB, Sparks DA. Spinal cord stimulation for visceral pain from chronic pancreatitis. Neuromodulation. 2011;14:423–427.CrossRefPubMed
65.
Midha S, Khajuria R, Shastri S, Kabra M, Garg PK. Idiopathic chronic pancreatitis in India: phenotypic characterization and strong genetic susceptibility due to SPINK1 and CFTR gene mutations. Gut. 2010;59:800–807.CrossRefPubMed
66.
Van Goor F, Hadida S, Grootenhuis PD, Burton B, et al. Correction of the F508delCFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA. 2011;108:18843–18848.CrossRefPubMedPubMedCentral
67.
Jih KY, Hwang TC. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proc Natl Acad Sci USA. 2013;110:4404–4409.CrossRefPubMedPubMedCentral
68.
Hayes D Jr, McCoy KS, Sheikh SI. Resolution of cystic fibrosis-related diabetes with ivacaftor therapy. Am J Respir Crit Care Med. 2014;190:590–591.CrossRefPubMed
69.
Bellin MD, Laguna T, Leschyshyn J, Regelmann W, et al. Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study. Pediatr Diabetes. 2013;14:417–421.CrossRefPubMedPubMedCentral
70.
Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007;447:87–91.CrossRefPubMed
71.
Alton EW, Armstrong DK, Ashby D, Bayfield KJ, et al. UK Cystic Fibrosis Gene Therapy Consortium. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebocontrolled, phase 2b trial. Lancet Respir Med. 2015;3:684–691.CrossRefPubMedPubMedCentral
72.
Zhou CH, Li ML, Qin AL, Lv SX, et al. Reduction of fibrosis in dibutyltin dichloride-induced chronic pancreatitis using rat umbilical mesenchymal stem cells from Wharton’s jelly. Pancreas. 2013;42:1291–1302.CrossRefPubMed
Metadata
Title
Novel and Experimental Therapies in Chronic Pancreatitis
Authors
Soumya Jagannath
Pramod Kumar Garg
Publication date
01-07-2017
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 7/2017
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4604-0

Other articles of this Issue 7/2017

Digestive Diseases and Sciences 7/2017 Go to the issue

Review

Epidemiology of Recurrent Acute and Chronic Pancreatitis: Similarities and Differences

Review

Endoscopic Management of Pancreatic Cysts

Review

Novel Biomarkers for Pancreatic Cysts

Review

Surgical Approaches to Chronic Pancreatitis: Indications and Techniques

Review

Insights into the Pathogenesis of Pancreatic Cystic Neoplasms

Review

Natural History of Pancreatic Cysts
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits